Skip to main content
✦Prime Rate:7.00%✦Fed Funds:3.88%✦5 Yr Treasury:4.95%↓✦10 Yr Treasury:5.10%↓✦30 Yr Treasury:5.43%↓✦30 Yr Mortgage:7.11%·Updated Nov 12, 2026✦Prime Rate:7.00%✦Fed Funds:3.88%✦5 Yr Treasury:4.95%↓✦10 Yr Treasury:5.10%↓✦30 Yr Treasury:5.43%↓✦30 Yr Mortgage:7.11%·Updated Nov 12, 2026
Rates
MD Hyperbaric

MD Hyperbaric

The total investment to open a MD Hyperbaric franchise ranges from $129,550 to $549,200. The initial franchise fee is $50,000. Ongoing royalties are 8% plus a 2% advertising fee.

What is the MD Hyperbaric franchise?

Dr. Martin O'Malley opened the first MD Hyperbaric center in 2021 at 360 East 72nd Street in Manhattan, New York, after seeing professional athletes and orthopedic patients struggle to access medical grade hyperbaric oxygen therapy. Co founded with board member Mark Wiseman and headquartered in West Orange, New Jersey, the brand began franchising in 2024 through MDH Franchisor LLC, a wholly owned subsidiary of MD Hyperbaric Holding Inc. By May 2025, the system had six operating locations, with projections of nearly 20 by the end of 2025 and at least 25 centers by the end of 2026. The global hyperbaric oxygen therapy market was valued at USD 3.98 billion in 2025 and is projected to reach USD 6.71 billion by 2034, a compound annual growth rate of 5.96%. PeerSense produced this analysis independently, without promotional content from MD Hyperbaric or its affiliates.

The global HBOT devices market was estimated at USD 3.41 billion in 2025 and is projected to reach USD 5.53 billion by 2035 at a CAGR of 4.95%. The medical hyperbaric chambers segment is forecast to reach USD 1.4 billion by 2033 at a CAGR of 6.9%. North America held 32% of global HBOT revenue in 2025. Its market was valued at approximately USD 197.66 million in 2022 and is projected to reach USD 251.39 million by 2030. Wound healing held the largest market share in 2024, supported by diabetic foot ulcers, pressure ulcers, aging demographics, and chronic disease. Other demand areas include neurological conditions, traumatic brain injury, PTSD, Long COVID, post surgical recovery, and sports rehabilitation. Franchised medical HBOT remains fragmented, with few established systems operating at scale. MD Hyperbaric uses FDA cleared and ASME PVHO 1 approved chambers, including the OxyHealth Fortius420. The category has expanding FDA recognized indications and demand beyond soft chamber wellness services.

The initial franchise fee is $50,000. An earlier Entrepreneur.com reference from December 2022 listed $75,000, suggesting the fee changed during the brand's early commercial period. Total investment is approximately $300,000 to $500,000, including equipment, buildout, and initial inventory. A detailed estimate includes $50,000 for the franchise fee, $10,000 for buildout net of tenant improvement allowance, $20,000 for fit and finish, $40,000 for working capital, and $280,000 for two HBOT chambers priced at $140,000 each. The chambers receive an exclusive franchise price compared with a retail price of $180,000 per unit, creating $80,000 in aggregate equipment savings. The total equity capital expenditure is $400,000, while the model can accommodate $240,000 in financed capital expenditure. Other FDD based estimates range from $129,550 to $524,200 and from $208,635 to $338,076, reflecting three format options. Royalties are 8% of gross sales, and the brand fund contribution is 2%, for total ongoing fees of 10% of revenue. One source lists a minimum net worth of $750,000. MDH Franchisor LLC is wholly owned by MD Hyperbaric Holding Inc., but the FDD does not provide parent company financial statements or a parent guarantee of franchisor obligations.

MD Hyperbaric offers Start Up locations within existing physician practices, Integration locations with dedicated branded areas in medical offices, and Flagship centers that generally contain four or more chambers. This structure lets buyers align capital and real estate with their existing resources. Locations use prequalified medical directors who follow protocols created by the company's medical leadership, with an emphasis on lean staffing and lower overhead. Training covers industry standard certification for medical directors, MD Hyperbaric operating procedures, and CRM and HR technology. Before opening, support includes site selection, real estate negotiations, architectural design, compliance, equipment procurement, and staff training. After opening, franchisees receive marketing programs, operating reviews, compliance evaluations, lead generation help, and business to business outreach support. Dr. Martin O'Malley is Chief Medical Officer and provides network wide medical oversight. Franchisees also receive access to a research library and shared operating practices. In February 2026, Dr. Jason Sonners became Chief Clinical Officer and Dave Globig became Chief Strategy Officer.

Because the disclosure reflects one franchised outlet, the sample is very limited. Buyers should obtain supporting records and conduct franchise validation calls before treating the results as a forecast. The franchisor's 2024 financial statements show a net loss of over $57,000 and negative net worth. The results should therefore be viewed as potential performance from an early system, not established network wide evidence.

MD Hyperbaric was founded in 2021 and began franchising in 2024. It signed 7 franchise agreements during its first franchising year, while only one franchised unit was open at the end of 2024. By May 2025, the system had six operating locations, with projections of close to 20 by year end 2025. A November 2024 announcement covered 7 new locations across New York, including the first three in Westchester, Syracuse, and Long Island, targeted to open in Q1 2025. The brand has set a target of 25 or more centers by the end of 2026. CEO Chris Neal, CMO Dr. Martin O'Malley, CCO Dr. Jason Sonners, and CSO Dave Globig combine clinical, franchise, and strategy experience. Its stated differentiators include physician founded leadership, FDA cleared OxyHealth Fortius420 chambers approved under ASME PVHO 1, centralized medical director oversight, and protocols developed under Dr. O'Malley's leadership. The concept serves both orthopedic and sports medicine patients and the broader proactive wellness market.

The primary target franchisees are physicians adding HBOT to existing practices, followed by healthcare adjacent professionals with clinical operations experience and entrepreneurs seeking a medically validated category. Physicians may select the Start Up or Integration formats, while entrepreneurs and investment groups may pursue a Flagship center with four or more chambers. Expansion is national, with priority on top ten U.S. markets, although current activity is concentrated in New York State because of the Manhattan origin and physician partnership model. Opening time will vary by format and buildout complexity. Pre opening assistance includes contractor coordination, architectural design management, and equipment procurement. The three level training program covers medical director certification, company operations, and CRM and HR platforms. The franchise system remains early, with limited experience managing a multi unit network at the corporate level. Buyers should address that risk during discovery and review the Item 21 financial statements.

MD Hyperbaric combines medical grade wellness services, the aging U.S. population, chronic disease demand, and community based clinical care. The global HBOT market is projected to reach USD 6.71 billion by 2034, while the North American segment is projected to grow from USD 197.66 million in 2022. The brand has expanded from one Manhattan clinic in 2021 to six operating locations, with an ambition of at least 25 centers by the end of 2026. Buyers should weigh the clinical model and market timing against the limited franchise track record. PeerSense provides independent due diligence data covering SBA lending history, Loan Activity Score, location maps with Google ratings, FDD financial data, and comparison tools.

According to its Franchise Disclosure Document or public business records, MD Hyperbaric has 1 location. Cost figures are based on the 2025 Franchise Disclosure Document. To correct a figure, email the current FDD and the differing item numbers to info@peersense.com, and this page will be updated.

2025 FDD ON FILEHealthcare

Est. 2021 · 1 location

Investment

$129,550 to $549,200

Franchise Fee

$50,000

Total Units

1

SBA Lending Activity for MD Hyperbaric

Loan Activity Score

This franchise has not yet been scored by the Franchise Performance Index. Scores are calculated based on public FDD data, SBA loan performance, and system level metrics.

Key Highlights

Item 19 financial data disclosed

Data Insights

Key performance metrics for MD Hyperbaric based on SBA lending data

Investment Tier

Significant investment

$129,550 to $549,200 total

Why MD Hyperbaric Doesn't Appear in Public SBA Data

The SBA 7(a) program publishes loan level data for every approved franchise borrower. MD Hyperbaric does not currently appear in those public records, and that absence carries useful information for prospective franchisees evaluating this brand.

Likely explanations for the absence

  • The brand began franchising recently (2 years ago). The SBA reporting pipeline trails new-franchise activity by 12 to 24 months.
  • With under 25 units system wide, transaction volume is small enough that any SBA activity could fall below the reporting visibility threshold in any given fiscal year.

Absence from SBA records does not mean a brand is un fundable. It typically means the franchise system uses alternative capital sources, or that current franchisees self fund, secure conventional bank financing, or roll over equity from a prior business sale rather than going through an SBA guaranteed 7(a) loan. For prospective MD Hyperbaric franchisees, the practical question is which financing path actually closes for this brand's profile.

Data window: SBA 7(a) approvals reported through the most recent FOIA release. Absence of MD Hyperbaric from this window does not reflect lender denial. It reflects no 7(a)-program activity recorded for this brand in the public dataset.

Payment Estimator

Loan Amount$104K
Interest Rate9.5%
Term (Years)10 yr

Estimated Monthly Payment

$1,341

Principal & Interest only

Indicative only, as of November 1, 2026. Not a quote, commitment or offer of credit. Final pricing, leverage and terms are determined by the lender at underwriting, after full transaction materials are reviewed. PeerSense sources the file. The lender sets pricing. What these terms mean.

Locations

MD Hyperbaric, unit breakdown

Total Units
N/A
Franchisee Owned
n/a
System Owned
n/a
Closed
n/a

Explore Funding for MD Hyperbaric

Our business financing consultants help connect you with the right lending partners. Referral fee paid at closing.

Optional: checking the consent box lets us call or text you about your funding. You can still submit without it.

Referral fee at closing

Or get an instant analysis

Scan Your Deal Instantly

1 FDD Available for MD Hyperbaric

Review franchise fees, investment ranges, royalties, Item 19 financial data, and year over year trends. Request complimentary access through your PeerSense funding advisor.

MD Hyperbaric

Page Review

Reviewed by Edward L. Freeman, Founder and Managing Director, PeerSense

  • PeerSense is a capital advisory firm that places commercial financing with direct capital sources; the capital source sets final terms.
  • Edward L. Freeman founded PeerSense in January 2020.
  • He is a Registered Franchise Consultant with Business Alliance, Inc., a credential issued in March 2022, and worked as a franchise consultant there from March 2022 to May 2023.
  • His recorded experience includes a $22 million SBA construction loan, with about $16 million funded on the deal.
  • In the 12 months through September 30, 2026, PeerSense tracked 912 publicly announced financings with a disclosed size of $361.32 billion. PeerSense Capital Data Report · Methodology page

Last reviewed LinkedIn profileAbout Edward Freeman

This is not a franchise offering and does not constitute financial, investment, or legal advice. Data is sourced from Franchise Disclosure Documents (FDDs), public filings, and third party sources and may contain inaccuracies. The figures reflect the FDD on file for the year shown and may have been superseded or extracted with errors. PeerSense is not a financial advisor, attorney, or accountant. Always consult the brand's current FDD and seek professional guidance from a qualified attorney, accountant, or financial advisor before making any franchise investment decision. See full Terms & Conditions.